Baskaran Pagadala
Baskaran Pagadala has 3 decades of experience in Operations including manufacturing, EHS, Projects and Operational Excellence. Prior to joining Sekhmet Pharmaventures he served various roles in Lupin, Hetero, Granules, Cipla and JK Pharma. Most recently he headed API – Operations role at Lupin.
Baskaran holds Masters in Chemical Engineering from JNTU
Ashwin Trinidad
Ashwin has over 25 years of experience in various Global, Multinational and Domestic Pharmaceutical and Chemical corporations working in the fields of Finance, Accounting, Treasury, Controlling, MIS, Internal Audit, Taxation and Commercial operations.
In his previous roles, he has been the CFO and Head of Legal & IT at Samara Capital-owned Oaknet Healthcare Pvt. Ltd. Prior to Oaknet, he has been the India Group CFO & Sr. Director, Finance for India & China regions for Teva Pharmaceuticals. He has also been the General Manager, Finance & Controlling at Merck Limited, a Company listed on the Indian Stock Exchange. He has been on the Board of Directors of Merck Specialities Pvt. Ltd. as well as on the Board of multiple Companies within the Teva Pharmaceutical group in India.
He has a strong track record in Business reviews, Strategy simulations, Due diligence, M&A, Capital Project Evaluation, Risk Management, Financial controls & ERP alignment.
Ashwin has a Masters’ degree in Financial Management from Narsee Monjee Institute of Management Studies, Mumbai University, is a Cost and Management Accountant (ACMA), a Company Secretary (ACS) and has a Graduate degree in Commerce, specializing in Financial Accounting from Mumbai University.
Aswin Vikram
Executive Director at PAG
On the Board of Acme Formulation since October 2021
13+ years of private equity experience with global mega funds like Blackstone and Bain Capital
Qualifications: Bachelor of Technology degree from the IIT, Madras; Post Graduate Diploma in Management from IIM, Bangalore
Mr. C Kalaichelvan
Mr. Kalaichelvan is the Founder and Director of Anjan Drug. Prior to founding Anjan in 1991, he has worked with Tamil Nadu Dadha Group and was in charge of the API division.
Deep technical expertise in API manufacturing, especially in CNS
Gil Feldman
Gil has more than 24 years of experience in various Sales, Marketing, R&D and high Leadership roles. Prior to joining Sekhmet Pharmaventures he fulfilled various roles at Teva and Teva API in regions like Israel, US & Canada and Japan. Most recently President (APAC region) for Teva API commercial operations. Before Teva, he spent 6 years with Netafim, a global leader in its industry, in R&D and Sales & Marketing leadership, and prior to this held vast experience of over 5 years in Management Consulting.
A strategic thinker with extensive experience in leading teams across regions engaging in cross-divisional projects.
Gil holds a B.Sc. degree in Industrial Engineering from Tel-Aviv University, and a Master’s in Business Administration (MBA) from the Technion in Israel.
Dr. D. Srinivasa Reddy
Dr D Srinivas Reddy is the Founder and Director of Optimus Group. His vision to leverage technological advancements in drug development & manufacturing, Innovation to provide cost-effective & affordable products to the people in need has driven the company’s objective.
Under Dr Srini’s leadership, Optimus has shown exponential growth, making it one of the fastest-growing Pharma companies based in India, with a worldwide presence. With over two decades of rich experience across all divisions, His guidance & support has proven vital to the company’s success.
Dr Srini holds MSc & PhD in Organic chemistry. Prior to Founding Optimus, Srini has been associated with Prestigious Pharma companies & MNC’s
Anchit Gupta
Anchit Gupta joined Samara Advisors in May 2012 and is Managing Director, investments in the firm.
He leads investments for the firm in certain sectors - Technology Services and Products, Pharmaceutical, Auto & Auto Ancillary and Media & Entertainment. He serves on the board of Cogenics, Oaknet Healthcare, SMS Integrated Facilities Management & Gamot (API Pharma platform) and is involved in More Retail Limited.
Previously, Anchit was at Kubera Partners and was involved in seven investments and two exits with more than USD 100 million at work across sectors such as technology, media services, automotive ancillary, education and biotechnology. Prior to Kubera, he was an analyst with the corporate finance practice at McKinsey & Co.
Anchit has an MBA from the Kellogg School of Management, Chicago and a B.Sc. in Computer Science from Delhi University. He also holds an MS (Finance) and a Chartered Financial Analyst (CFA) Charter from ICFAI University, Hyderabad.
Vivek Chhachhi
Prior to joining the Investment Advisor in 2010, Mr. Chhachhi was a Director with CVCI, where he had about 15 years of investing experience. During his tenure with CVCI, Mr. Chhachhi worked to identify, manage and exit a large number of companies across a wide spectrum of industries including, among others, IT, pharmaceutical and specialty chemicals, IT enabled services, financial services, auto, metals and mining, infrastructure, oil and gas services, media and textiles. Prior to CVCI, Mr. Chhachhi had two years of experience as an equity research analyst at a Citi-affiliated brokerage firm, Citicorp Securities & Investments Limited. Mr. Chhachhi has served on the boards of the following Fund 1 portfolio companies — Thyrocare, Nueclear, Thyrocare Gulf, Sutures and Natco. Prior to this, Mr. Chhachhi also served as a board member or as an observer on the board of several CVCI portfolio companies, such as i-FLEX, Jubilant Organosys, Sasken Technologies, RelQ Software, Newgen Software, Himadri Industries, Techno Electric, IVRCL, Perlecan Pharma, International Tractors, Jai Balaji, and Globe Capital, among others. Mr. Chhachhi earned a master’s degree in Management Studies from the Jamnalal Bajaj Institute of Management Studies, University of Mumbai and a B.Sc. degree in Computer Science from St. Stephen's College, Delhi University.
Nikhilkumar Srivastava
Nikhil Srivastava is a Partner and Managing Director, Head of India Private Equity at PAG, one of Asia's largest alternative investment managers with USD 45 billion in assets under management. He started PAG's India office and is currently investing from a USD 6 billion private equity fund. Prior to joining PAG, Mr. Srivastava spent almost a decade at KKR in India, Singapore, and the United States. Previously, he worked in investment banking at Goldman Sachs and was an early employee at Inphi (NYSE: IPHI). Mr. Srivastava has an MBA from Harvard Business School, a Masters in Electrical Engineering from Stanford University and a Bachelors in Electrical Engineering from BITS-Pilani where he graduated as University gold medallist. He is the author of several patents.
Anil Khubchandani
Anil has over 30 years of diverse experience across technical, commercial and managerial roles in the Life Science Industry. Before joining Sekhmet Pharmaventures, Anil was the Co- CEO & Whole-time Director at Jubilant Ingrevia Limited and has served as a strategic business leader, developed high-performing teams, and oversaw solutions and offerings of the company to the global customers. He also spearheaded several Global CDMO assignments and new business initiatives for Pharmaceutical Innovator companies.
Anil has an exemplary academic track record and is an alumnus of premium institutes like the Indian Institute of Technology (IIT), Indian Institute of Management (IIM), & Kellogg School of Management. He holds a B.Tec degree in Chemical Engineering from IIT, Varanasi , and holds Management certifications from IIM-Calcutta & Kellogg School of Management, Northwestern University, Illinois, USA.